Iboga Entactogens
Tech ID: 34762 / UC Case 2024-575-0
Abstract
Researchers at the University of California, Davis have
developed ibogaine-related compounds that promote neural plasticity and treat
neuropsychiatric and neurological disorders.
Full Description
This technology features novel
ibogaine analogues and their pharmaceutically acceptable salts designed to
increase dendritic spine density and enhance neural plasticity. These compounds
may modulate serotonin transporter function and/or activate serotonin receptors,
fostering neuronal growth and improved neuronal architectures, potentially
reversing structural brain alterations seen in various brain disorders. The
synthetic strategies allow efficient production of natural and non-natural
iboga alkaloid analogues, showing promise for treating neuropsychiatric
conditions such as depression, addiction, and anxiety.
Applications
- Treatment of depression, anxiety, and addictive disorders.
- Treatment of traumatic brain injury.
- Neuropsychiatric disorder therapies targeting
brain structure restoration.
- Neurodegenerative and neurological disease
interventions promoting neuronal growth.
- Pharmaceutical development of
neuroplasticity-enhancing drugs.
- Research tools for studying serotonin transporter modulation
and synaptic plasticity.
Features/Benefits
- Promotes cortical neuron growth and enhances
neuroplasticity.
- Modulates serotonin transporter/receptor
activity to support therapeutic effects.
- Improves synaptic connectivity by targeting
plasticity deficits at the neuronal level.
- Demonstrates antidepressant, anxiolytic, and
anti-addictive activity in preclinical studies.
- Accelerates lead optimization by enabling
selective, efficient synthesis of multiple analogues with tunable
modifications.
- Reverses loss of dendritic spines and synapses
associated with brain disorders.
- Restores dendritic arbor complexity to improve
neuronal communication.
- Expands therapeutic options for neuropsychiatric
and neurological diseases marked by synaptic deficits.
- Addresses the lack of compounds that strengthen
top-down control of motivation, fear, reward, and cognition.
- Delivers candidates that produce rapid and durable
structural improvements in neurons.
Patent Status
| United States Of America |
Published Application |
20260055109 |
02/26/2026 |
2024-575 |
| |
|